TOP HEADLINES

FEATURED STORY

EMA still wants 700 GVK-related drugs off the market

The European Medicines Agency has affirmed its January recommendation, calling for the suspension of more than 700 products tied to improprieties at a GVK Biosciences facility in India.

BioClinica partners up for risk-based management

BioClinica has inked a deal with consulting firm Kinapse to help spread the adoption of its risk-based monitoring service, a targeted approach to keeping tabs on trials.

DaVita's in-house CRO stretches out across Europe

DaVita Clinical Research, which handles outsourced trials for the kidney care giant, is expanding its European presence, bringing in global experts to extend its network of R&D sites.

Parexel rejigs its randomization tech with an eye on speed

CRO giant Parexel has updated its technology for patient randomization and clinical supply management, touting the latest version as a valuable tool for speeding up the process of designing studies.

WuXi's CEO moves to take the CRO private

WuXi PharmaTech's CEO has teamed up with a major investor in an attempt to take the CRO private, pitching a buyout that would give the Chinese company's shareholders a 16.2% premium.

MORE NEWS

From Our Sister Sites

FierceBiotech

Bristol-Myers Squibb and rival Merck started off the big annual scientific meeting of  ASCO  with a bang, rolling out a slate of new studies spotlighting the growing body of evidence that their new immuno-oncology drugs will play a key role fighting a range of cancers.

FierceAnimalHealth

Danish enzyme maker Novozymes is answering the call for alternatives to animal antibiotics by entering the market for probiotics--the so-called good bacteria that are believed to boost growth and prevent the buildup of bad bugs in animals' guts.